Scientific insights: CKD
VibeOne analyzed 100+ CKD programs and found a clear pattern: small molecules dominate and repurposed drugs win. The next kidney breakthrough may already be in a cardiovascular trial.
Scientific insights
-
-
Scientific insights:The ActRIIB Challenge (LAE103)
The obesity market is undergoing a quiet revolution: it’s no longer about how much weight patients lose, but what kind of weight they lose.
-
Scientific insights: Urea cycle disorders
Drug hunters need to watch Urea Cycle Disorders! Gene therapies (cost) and ERTs (patient experience) still leave much to be desired.
-
Scientific insights: Kidney disease
Explore why kidney disease is emerging as a top therapeutic focus. See how VibeOne identifies high-potential kidney indications and guides strategic prioritization.
-
Scientific insights: Fabry disease
Fabry disease may seem niche, but it’s becoming a bellwether for how global innovation and modality shifts are reshaping rare disease pipelines.
